While ORRs were similar (TBx-pos 54.3% vs. LBx-pos 51.7%), time-dependent outcomes trended shorter in LBx-positive patients. 📉 mPFS: 13.7 mo (TBx) vs. 8.9 mo (LBx). 📉 Median OS: 22.9 mo (TBx) vs. 17.6 mo (LBx)

New research from the #VISION trial of #tepotinib in #NSCLC with #METex14 skipping highlights key differences when patients are identified by LBxvs TBx.
➡️ #Tepotinib showed robust efficacy regardless of biopsy type
@christianrolfo.bsky.social @oncoalert.bsky.social

Visit at #AACR25 the poster by Dr. Eswar Shankar on “Synergistic Inhibition of TNBC via EZH2 inhibition and D1 Receptor Agonism”
@OSUCCC_James

@osuwexmed.bsky.social
@christianrolfo.bsky.social
@theaacr.bsky.social
pbs.twimg.com/media/Gpay9i...

Great panel discussion on the session about early cancer detection at #ISLB24

So many options and ideas for cancer research! 🎯🔍

@christianrolfo.bsky.social
#JacobBerchuck
#trevorPugh
#martaDuenas

@internationalsocietyofliquidbiopsy

Second day at #ISLB24 with @christianrolfo.bsky.social presenting data on early cancer detection in different cancer types!

—> is possible but there are many different LB 🩸 method that must be integrated with AI 🤖

@internationalsocietyofliquidbiopsy
@ohiostatepress.bsky.social

LB - Tissue

Detection of gene copy number (CN) losses (PTEN, BRCA1/2, PALB2) in prostate, breast and ovarian cancer.

--> High concordance (liquid/tissue) in samples with Tumor Fraction ≥ 20% (sensitivity 83%)

#ISLB24
@christianrolfo.bsky.social
@internationalsocietyofliquidbiopsy

Super poster session! 🧨
@UmbertoMalapel1
shows us how an algorithm can filter out genomic alterations while analyzing LB sample in a prostate cancer cohort of patients!

#ISLB24

@isliquidbiopsyhttps://x.com/RobertoBoreaMD/status/1860412702520205367/photo/1

Brilliant presentation by @christianrolfo.bsky.social from OSUCCC on ctDNA fragmentation in solid tumors!

🔑 message
ctDNA fragmentation is emerging as a new tool to better understand and use LB in the management of cancer patients!

@umbertomalapelle1
@stoverlab.bsky.social

Nice to meet great international colleagues/researchers at #ISLB24! 🌎

Ready for this great event to share knowledge about liquid biopsy! 🔥

@internationalsocietyofnliquidbiopsy
@christianrolfo.bsky.social
@umbertomalapelle
@brunapellini
@robertoboreamd.bsky.social
@mariantonianacchio

The annual International Society of Liquid Biopsy #ISLB is starting now in Denver.

No better way to celebrate the beginning of this event than with a picture of the president of ISLB @christianrolfo.bsky.social and the secretary of ISLB @umbertomalapelle

Ready to kick of! 🩸🧬

📚 Important brainstorming on the need for integration of Liquid Biopsy 🩸 and Response Evaluation Criteria in Solid Tumors (LB-RECIST) and great collaboration with ⁦✨ @mgoudaMD @VivekSubbiah @curijoey @Annals_Oncology @christianrolfo.bsky.social

www.annalsofoncology.org/article/S092...

Our study at @jlb_islb 📚
🔮 🧬 “Extracellular Vesicles As Mediators of Resistance to EGFR-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Preclinical Models”
@ddemiguelperez @isliquidbiopsy @EGFRResisters @EgfrUk @EGFRmNSCLC @christianrolfo.bsky.social

id.elsevier.com/as/authoriza...

EVs play an important role in viral infection & immune response, they could potentially serve as predictive & prognostic biomarkers. Here immunogold TEM revealing EVs from BAL similar diameter with presence of CD9 and S by binding to nanogold particles of 5 & 10 nm
@ISEV_JExBio

🚨 Our work is open access at @ISEV_JExBio

🦠 "Extracellular vesicles containing SARS-CoV-2 proteins are associated with multi-organ dysfunction and worse outcomes in patients with severe COVID-19”

isevjournals.onlinelibrary.wiley.com/doi/epdf/10....

@christianrolfo.bsky.social